Clinical trials
DMD clinical trials
Below are recruiting dmd clinical trials, each written for real people, not researchers. We’re tracking 43 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06900049RecruitingEarly Phase 1
Testing LE051 for boys with Duchenne muscular dystrophy (exon 51)
This study tests a new medicine called LE051 for boys with Duchenne muscular dystrophy (DMD) who have a specific genetic change that allows 'exon 51 skipping.' The goal is to see if it is safe and can help improve muscle function. Boys who join will be closely monitored for heart and lung health.
Shanghai, Shanghai MunicipalityAges 4–8 - NCT07172971RecruitingPhase 1
SGLT2i drug for heart health in Duchenne muscular dystrophy
This trial tests if an SGLT2i medication can help protect heart function in people with Duchenne muscular dystrophy (DMD). The drug is already approved for other conditions, and researchers want to see if it can slow or prevent heart muscle damage.
Nashville, TennesseeAges 8–18 - NCT07129954Recruiting
Fear of Falling in Muscular Dystrophy Trial
This trial tests a treatment to help people with certain types of muscular dystrophy who are afraid of falling. It aims to improve confidence and walking safety.
Verona, veronaAges 16–65 - NCT07092540Recruiting
Baby Duchenne Study: Early Years in Boys With DMD
This study tracks development and health in young boys with Duchenne muscular dystrophy during the first three years of life. It aims to better understand early signs and how the condition progresses, which may help improve care and future treatments.
Rochester, New YorkAges birth–3 years - NCT07058662RecruitingPhase 1/Phase 2
Gene therapy study for Duchenne muscular dystrophy in boys 4-8
This study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy. The goal is to see if it is safe and can help improve muscle function. It is for boys aged 4 to 8 who can still walk.
Beijing, Beijing MunicipalityAges 4–9 - NCT07038824RecruitingPhase 1/Phase 2
A study of ENTR-601-45 for Duchenne MD (exon 45 skipping)
This trial tests an experimental drug called ENTR-601-45 for people with Duchenne muscular dystrophy that can be treated with 'exon 45 skipping.' The goal is to see if it's safe and helps improve muscle function. It's for males between 4 and 20 who can still walk and have enough arm strength.
GhentAges 4–20 - NCT07037862RecruitingPhase 1/Phase 2
Study of ENTR-601-44 for Duchenne muscular dystrophy (exon 44 skipping)
This trial tests a new medicine called ENTR-601-44 for people with Duchenne muscular dystrophy whose genetic mutation can be treated by skipping a part of the gene called exon 44. The goal is to see if it is safe and helps with muscle function.
GhentAges 4–20 - NCT07039799Recruiting
Virtual reality for arm function in Duchenne
This trial tests whether using virtual reality (VR) games can help improve arm and hand function in people with Duchenne muscular dystrophy. It may be a fun and engaging way to do exercises that strengthen your upper body.
Istanbul, FatihAges 7–18 - NCT06887491Enrolling by invitation
Dual-tasking (thinking + moving) program for children with Duchenne MD
This study tests whether a special program that combines thinking tasks (like counting or remembering) with physical activities can help boys with Duchenne muscular dystrophy improve their thinking, movement, and ability to do everyday tasks independently.
Ankara, CankayaAges 6–12 - NCT06867107Enrolling by invitationPhase 2
Long-term follow-up study of SAT-3247 for Duchenne muscular dystrophy
This study follows people with Duchenne muscular dystrophy who were in an earlier SAT-3247 trial, or who meet certain other criteria, to see how the medicine works over a longer time. It aims to gather more safety and effectiveness information.
Los Angeles, CaliforniaAges 16–40 - NCT06839469Recruiting
Walking study for rare muscle and nerve conditions
This study looks at how children and teens with Duchenne muscular dystrophy (DMD) or spinal muscular atrophy (SMA) walk, by having them do walking tests while wearing sensors. The goal is to find better ways to track how these diseases progress and how treatments work over time, without needing blood tests or scans.
Palo Alto, CaliforniaAges 5 years+ - NCT06769633RecruitingPhase 2
Study of givinostat in young boys with Duchenne muscular dystrophy
This trial tests an experimental drug called givinostat in boys ages 2 to under 6 years with Duchenne muscular dystrophy (DMD). The study looks at how the drug works in the body and if it is safe, with the goal of finding new treatment options for young children.
BrusselsAges 2–6 - NCT06692426RecruitingPhase 1
Cell therapy for Duchenne muscular dystrophy
This trial tests a new cell-based treatment for Duchenne muscular dystrophy in adults who can no longer walk. The goal is to see if the therapy can help improve muscle function.
Minneapolis, MinnesotaAges 18 years+ - NCT06124196Recruiting
Wearable device study for Duchenne muscular dystrophy
This study uses a wearable device to track your blood sugar levels and heart rate patterns over time. It aims to understand how these are related to Duchenne muscular dystrophy (DMD) and may help improve care.
Nashville, TennesseeAges 10 years+ - NCT06093100Recruiting
Wearable device study for Duchenne muscular dystrophy
This study uses a wearable device to track blood sugar levels and heart rate in people with Duchenne muscular dystrophy. It aims to understand how these factors relate to heart health over time.
Nashville, TennesseeAges 10 years+ - NCT05715957Enrolling by invitation
Follow-up study for women who carry a DMD gene change
This study follows women who have a confirmed DMD gene mutation (a genetic change related to Duchenne/Becker muscular dystrophy) to learn more about health and muscle-related measurements. Depending on the part of the study, you may be asked to take part in MRI or other assessments.
CopenhagenAges 18 years+ - NCT05412394RecruitingPhase 4
Once-weekly steroid for very young children with DMD
This trial tests whether a steroid taken once each week is safe and useful for children with Duchenne muscular dystrophy (DMD). It aims to help slow disease effects in very young children whose diagnosis and lab tests confirm DMD.
Chicago, IllinoisAges 1 month–2.5 years - NCT05102916Recruiting
Registry for neuromuscular disorder patients in Switzerland
This study is a patient registry that collects health information from people diagnosed with a neuromuscular disorder in Switzerland. It helps researchers better understand these conditions and how they vary from person to person.
Aarau, Canton of AargauAges birth+ - NCT04626674RecruitingPhase 1
Gene therapy for non-ambulatory Duchenne muscular dystrophy
This study tests a gene therapy that aims to help muscles produce a protein they are missing. It is for people with Duchenne muscular dystrophy who are no longer able to walk, and it may help slow the progression of the disease.
Little Rock, ArkansasAges 2 years+
Hear when a new DMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for dmd?
- Yes. Clin2 currently lists 43 recruiting dmd studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dmd trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dmd trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.